tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Labyrinthitis D007762 2 associated lipids
Paraproteinemias D010265 2 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Pityriasis Lichenoides D017514 2 associated lipids
Intracranial Thrombosis D020767 2 associated lipids
Fungemia D016469 2 associated lipids
Neuromyelitis Optica D009471 2 associated lipids
Pharyngitis D010612 2 associated lipids
Carcinoma, Merkel Cell D015266 2 associated lipids
Foot Deformities, Acquired D005531 2 associated lipids
Leg Injuries D007869 2 associated lipids
Hemolytic-Uremic Syndrome D006463 2 associated lipids
Lupus Erythematosus, Cutaneous D008178 2 associated lipids
Histiocytosis D015614 2 associated lipids
Seminoma D018239 2 associated lipids
Trauma, Nervous System D020196 2 associated lipids
Kartagener Syndrome D007619 2 associated lipids
Lichen Sclerosus et Atrophicus D018459 2 associated lipids
Pancreatic Fistula D010185 2 associated lipids
Dermatomyositis D003882 2 associated lipids
Rupture D012421 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Dental Enamel Hypoplasia D003744 2 associated lipids
Cheilitis D002613 2 associated lipids
Respiratory Tract Neoplasms D012142 2 associated lipids
Earache D004433 2 associated lipids
Leukemia, Biphenotypic, Acute D015456 2 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Skin Diseases, Viral D017193 2 associated lipids
Trichomonas Vaginitis D014247 2 associated lipids
Tongue Diseases D014060 2 associated lipids
Granulomatosis, Orofacial D051261 2 associated lipids
Nail Diseases D009260 2 associated lipids
Dental Pulp Calcification D003784 2 associated lipids
Skin Diseases, Papulosquamous D017444 2 associated lipids
Candidiasis, Invasive D058365 2 associated lipids
Telangiectasis D013684 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
IgA Deficiency D017098 2 associated lipids
Neuroaspergillosis D020953 2 associated lipids
Delayed Graft Function D051799 2 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Venous Insufficiency D014689 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Hypopigmentation D017496 2 associated lipids
Incontinentia Pigmenti D007184 2 associated lipids
Vitiligo D014820 2 associated lipids
Rectal Fistula D012003 2 associated lipids
Hidradenitis Suppurativa D017497 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Swanson C et al. FK 506-based immunosuppression in clinical pancreas transplantation. 1995 Transplant. Proc. pmid:8539827
Murase N et al. FK 506 prevents spontaneous diabetes in the BB rat. 1991 Transplant. Proc. pmid:1703705
Watanabe K et al. Donor bone marrow cell facilitates induction of tolerance to kidney allografts in dogs treated with fractionated lymphoid irradiation and FK 506. 1991 Transplant. Proc. pmid:1703706
Kobayashi N et al. Significance of pancreatic allograft rejection in swine abdominal organ cluster transplantation. 1991 Transplant. Proc. pmid:1703707
Khalaf H et al. Tacrolimus (FK 506) given three times daily after liver transplantation for minimizing nephrotoxicity and neurotoxicity. 2003 Transplant. Proc. pmid:14612120
Gamboa O et al. Cost-effectiveness analysis of the early conversion of tacrolimus to mammalian target of rapamycin inhibitors in patients with renal transplantation. 2011 Transplant. Proc. pmid:22099798
Kumar MS et al. ATGAM versus OKT3 induction therapy in cadaveric kidney transplantation: patient and graft survival, CD3 subset, infection, and cost analysis. 1998 Transplant. Proc. pmid:9636549
Yu L et al. Clinical experience with Prograf (tacrolimus, FK 506) in Chinese patients after renal transplantation. 2000 Transplant. Proc. pmid:11119902
Tang J et al. Cytokine Profile in Calcineurin Inhibitor-Induced Chronic Nephrotoxicity in Chinese Liver Transplant Recipients. 2016 Transplant. Proc. pmid:27788813
Corry RJ et al. Tacrolimus without antilymphocyte induction therapy prevents pancreas loss from rejection in 123 consecutive patients. 1998 Transplant. Proc. pmid:9532157
Wasserberg N et al. Tacrolimus does not upregulate mucin gene expression after small bowel transplantation in rats. 2003 Transplant. Proc. pmid:12644089
Fernández A et al. Complete switch to everolimus in long-term kidney transplants: evolution of the renal function. 2009 Jul-Aug Transplant. Proc. pmid:19715915
Alarcón-Zurita A et al. Steroids withdrawal after 3 months of successful renal transplantation using a tacrolimus- and mycophenolate-based immunosuppression. 2002 Transplant. Proc. pmid:11959216
Hoffman AL et al. The effect of FK 506 on small intestine allotransplantation in the rat. 1990 Transplant. Proc. pmid:1689907
Moochhala SM et al. Inhibition of drug metabolism in rat and human liver microsomes by FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1721277
Pan F et al. Effect of tacrolimus and splenectomy on engraftment and GVHD after bone marrow xenotransplantation in the reciprocal hamster to rat animal models. 1996 Transplant. Proc. pmid:8623373
Takada Y et al. Improvement of allograft viability with organs procured from non-heart-beating donors in porcine liver transplantation. 2000 Transplant. Proc. pmid:10715416
Land W et al. Mycophenolate mofetil monotherapy: an optimal, safe, and efficacious immunosuppressive maintenance regimen in kidney transplant patients. 2001 Transplant. Proc. pmid:11406265
Nakamura M et al. Clinical and radiological features of two cases of tacrolimus-related posterior leukoencephalopathy in living related liver transplantation. 1998 Transplant. Proc. pmid:9636600
Imamura M et al. FK 506 inhibits severe graft-versus-host disease without mediating cytokine balance and/or cytotoxic molecules. 2000 Transplant. Proc. pmid:11120238
Charco R et al. Hypercholesterolemia in long-term survivors of liver transplantation: a comparison between cyclosporine and FK 506. 1998 Transplant. Proc. pmid:9636605
Jang HJ et al. Comparison of pancreas transplantation outcome between the cyclosporine and tacrolimus eras. 2000 Transplant. Proc. pmid:11120249
Squifflet JP et al. The Benelux experience with the combination of tacrolimus and mycophenolate mofetil. 1999 Transplant. Proc. pmid:10576050
Tekgündüz E et al. Electrolyte free water clearance could be an early sign of renal dysfunction in renal transplant patients. 2009 Transplant. Proc. pmid:19917375
Resch B et al. FK 506 and successful pregnancy in a patient after renal transplantation. 1998 Transplant. Proc. pmid:9474990
Furlan V et al. Interaction between tacrolimus and itraconazole in a heart-lung transplant recipient. 1998 Transplant. Proc. pmid:9474996
Zawiasa A et al. Effect of oral fructose load on serum uric acid and lipids in kidney transplant recipients treated with cyclosporine or tacrolimus. 2009 Jan-Feb Transplant. Proc. pmid:19249511
Schwartz M et al. FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US Multicenter FK 506 Dose Optimization. 1995 Transplant. Proc. pmid:7533355
de Paulis A et al. Antiinflammatory effect of FK 506 on human basophils. 1991 Transplant. Proc. pmid:1721309
Kuriata-Kordek M et al. The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics. 2003 Transplant. Proc. pmid:14529944
Wojewodzka J et al. Inhibition of formation of synapses between dendritic cells and lymphocytes in skin lymph in an allogeneic reaction by cyclosporine and tacrolimus. 2003 Transplant. Proc. pmid:14529947
Chiang Y et al. Posttransplantation Kaposi sarcoma-experience in a patient receiving FK-506 and MMF. 2003 Transplant. Proc. pmid:12591389
Suga A et al. Diabetes mellitus after renal transplantation under tacrolimus-based immunosuppression. 2003 Transplant. Proc. pmid:12591391
Borrows R et al. Tacrolimus monitoring in renal transplantation: a comparison between high-performance liquid chromatography and immunoassay. 2005 Transplant. Proc. pmid:15919448
Koefoed-Nielsen PB et al. Comparison of the temporal profile of calcineurin inhibition by cyclosporine and tacrolimus in renal transplant patients. 2005 Transplant. Proc. pmid:15919449
Grochowicz PM et al. Synergism of castanospermine and FK 506. 1995 Transplant. Proc. pmid:7533408
Tamura K et al. Inhibition of insulin production by FK 506 is caused at the transcriptional level in pancreatic beta cell when FK BP-12 content is relatively high. 1995 Transplant. Proc. pmid:7533409
Reding R et al. Compassionate use of FK 506 in pediatric liver transplantation: a pilot study. 1991 Transplant. Proc. pmid:1721341
Lee KK et al. Comparison of short-term immunosuppressive therapy with cyclosporine and FK 506 in small-bowel transplantation. 1990 Transplant. Proc. pmid:1702239
Uemoto S et al. Experience with FK 506 in living related donor liver transplantation. 1991 Transplant. Proc. pmid:1721342
Charco R et al. Changes in renal function in long-term survivors of liver transplantation: a comparison between cyclosporine microemulsion and tacrolimus therapy. 2002 Transplant. Proc. pmid:12176478
Yokoyama I et al. Immunosuppressant effect on Fas antigen expression and p53 of an experimental tumor. 1998 Transplant. Proc. pmid:9865346
Bortman GV et al. South American Heart Transplantation Registry of patients receiving everolimus in their immunosuppressive regimens. 2010 Jan-Feb Transplant. Proc. pmid:20172342
Strassburg A et al. Basiliximab reduces acute liver allograft rejection in pediatric patients. 2002 Transplant. Proc. pmid:12270443
Rifai K et al. Severe hearing loss after liver transplantation. 2005 Transplant. Proc. pmid:15919504
Miller J et al. FK 506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study. The FK 506 Kidney Transplant Study Group. 1997 Feb-Mar Transplant. Proc. pmid:9123008
Kilinç M et al. FK 506-induced fulminant leukoencephalopathy after kidney transplantation: case report. 2002 Transplant. Proc. pmid:12072309
Toyama Y et al. Prolonged small bowel graft survival using photochemotherapy and low-dose FK 506. 1996 Transplant. Proc. pmid:8907924
Takahashi K et al. Successful results after 3 years' tacrolimus immunosuppression in ABO-incompatible kidney transplantation recipients in Japan. 2002 Transplant. Proc. pmid:12176502
Meçule A et al. Interleukin-2 profiles shortly after tacrolimus conversion from a twice-daily to once-daily regimen. 2011 Transplant. Proc. pmid:21620040
Chen CL et al. FK 506 used as rescue therapy for refractory liver allograft rejection. 1994 Transplant. Proc. pmid:7520612
Deuse T et al. Is the malononitrilamide FK778 better for the prevention of acute or chronic rejection? 2007 Transplant. Proc. pmid:17362784
Hebert MF et al. Efficacy and toxicity of FK 506 for the treatment of resistant rejection in liver transplant patients. 1991 Transplant. Proc. pmid:1721373
Eiras G et al. Effects of FK 506 and cyclosporine on T-cell activation: integrin-mediated adhesion of T cells, proliferation, and maturation of cytotoxic T cells. 1991 Transplant. Proc. pmid:1703357
Humar A et al. Surgical complications requiring early relaparotomy after pancreas transplantation: comparison of the cyclosporine and FK 506 eras. 1999 Feb-Mar Transplant. Proc. pmid:10083256
Shapiro R et al. Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature. 1997 Transplant. Proc. pmid:9290809
Wijnen RM et al. Thymus atrophy in the nonhuman primate by FK506: an immunohistochemical study. 1997 Feb-Mar Transplant. Proc. pmid:9123292
Kumano K et al. Role of the transforming growth factor and monocyte chemoattractant protein in FK506-induced nephropathy in the rat. 1997 Feb-Mar Transplant. Proc. pmid:9123293
Bilbao I et al. Comparison between tacrolimus and neoral cyclosporine administered by oral route in liver transplantation. 2001 Transplant. Proc. pmid:11377472
Braun F et al. Clinical relevance of monitoring tacrolimus: comparison of microparticle enzyme immunoassay, enzyme-linked immunosorbent assay, and liquid chromatography mass spectrometry in renal transplant recipients converted from cyclosporine to tacrolimus. 1996 Transplant. Proc. pmid:8962231
Grochowicz PM et al. Synergistic interaction between castanospermine and tacrolimus in a rat heart allograft model. 1997 Feb-Mar Transplant. Proc. pmid:9123296
van Duijnhoven EM et al. Evidence that fasting does not significantly affect trough levels of tacrolimus in stable renal transplant recipients. 2002 Transplant. Proc. pmid:12176552
Braun F et al. Pharmacokinetics of tacrolimus primary immunosuppression in kidney transplant recipients. 2001 Transplant. Proc. pmid:11377473
Wilczek HE et al. Renal transplant histopathologic changes during the first year in patients with tacrolimus (FK 506). 1996 Transplant. Proc. pmid:8962232
Saito K et al. Study of pharmacokinetic parameters of tacrolimus by different oral administration periods in renal transplantation. 2002 Transplant. Proc. pmid:12176553
Yussim A et al. Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation. 1996 Transplant. Proc. pmid:8962233
Toraishi T et al. Falsely abnormally elevated blood trough concentration of tacrolimus measured by antibody-conjugated magnetic immunoassay in a renal transplant recipient: a case report. 2012 Transplant. Proc. pmid:22310597
Yoshimura R et al. A comparative study of cyclosporine vs FK 506: role of kidney microsomal cytochrome P-450. 1992 Transplant. Proc. pmid:1379755
Baruch Y et al. Anasarca and hypertrophic cardiomyopathy in a liver transplant patient on FK506: relieved after a switch to Neoral. 1996 Transplant. Proc. pmid:8769215
Abu-Elmagd KM et al. Acute hemolytic anemia in liver and bone marrow transplant patients under FK 506 therapy. 1991 Transplant. Proc. pmid:1721404
Yamada K et al. FK 506-induced juxtaglomerular apparatus hyperplasia and tubular damage in rat kidney--morphologic and biologic analysis. 1992 Transplant. Proc. pmid:1379756
Melter M et al. Successful reconversion from tacrolimus to cyclosporine A Neoral in pediatric liver recipients. 1996 Transplant. Proc. pmid:8769224
Ishibashi M et al. Immunopharmacologic effects of immunosuppressive agents explored by a new effector monocyte generation assay. 1989 Transplant. Proc. pmid:2469228
Ettenger R The practical problems of prednisone in pediatric renal transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267159
Takahashi Y et al. Pharmacokinetic Profile of Twice- and Once-daily Tacrolimus in Pediatric Kidney Transplant Recipients. Transplant. Proc. pmid:28104153
Boletis J et al. Delayed renal graft function: the influence of immunosuppression. 2005 Transplant. Proc. pmid:15964337
Reggiani P et al. Reduced acute rejection after liver transplantation with Neoral-based double immunosuppression. 1998 Transplant. Proc. pmid:9723308
Levy GA Neoral use in the liver transplant recipient. 2000 Transplant. Proc. pmid:10814745
Lauro A et al. Liver transplantation for familial amyloid polyneuropathy non-VAL30MET variants: are cardiac complications influenced by prophylactic pacing and immunosuppressive weaning? 2005 Transplant. Proc. pmid:15964382
Russ GR et al. Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients. 2003 Transplant. Proc. pmid:12742480
Ciancio G et al. Effect of daclizumab, tacrolimus, and mycophenolate mofetil in pediatric first renal transplant recipients. 2002 Transplant. Proc. pmid:12176637
El-Sabrout R et al. Improved lipid profile and blood sugar control in pediatric renal transplant recipients using sirolimus-tacrolimus combination. 2002 Transplant. Proc. pmid:12176638
Doesch AO et al. Increased adherence after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation: a pre-experimental study. 2010 Transplant. Proc. pmid:21168673
Moray G et al. Comparison of histidine-tryptophan-ketoglutarate and University of Wisconsin in living-donor liver transplantation. 2006 Transplant. Proc. pmid:17175334
Rayhill SC et al. A cyclosporine-based immunosuppressive regimen may be better than tacrolimus for long-term liver allograft survival in recipients transplanted for hepatitis C. 2006 Transplant. Proc. pmid:17175350
Kuroki H et al. Synergistic effect of FK 506 and donor-specific blood transfusion on rat skin but not on composite tissue (limb) allograft survival. 1991 Transplant. Proc. pmid:1721436
Ito T et al. Bone marrow cell- and FK 506-induced donor-specific unresponsiveness in rat heart allografts. 1991 Transplant. Proc. pmid:1721437
Todo S et al. Orthotopic liver transplantation in dogs receiving FK-506. 1987 Transplant. Proc. pmid:2445079
Lim SM et al. Heterotopic heart transplantation in the rat receiving FK-506. 1987 Transplant. Proc. pmid:2445080
Jain A et al. Prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil: complete report on 350 primary adult liver transplantations. 2001 Feb-Mar Transplant. Proc. pmid:11267319
Mueller AR et al. Influence of immunosuppression on patient survival after liver transplantation for hepatitis C. 2001 Feb-Mar Transplant. Proc. pmid:11267321
Krämer BK et al. Efficacy of Prolonged- and Immediate-release Tacrolimus in Kidney Transplantation: A Pooled Analysis of Two Large, Randomized, Controlled Trials. 2017 Transplant. Proc. pmid:29149958
Cofan F et al. Fatty acid composition in low-density lipoproteins from renal transplant recipients. 1999 Transplant. Proc. pmid:10500603
Alvarez-Elías AC et al. CYP3A5 Genotype and Time to Reach Tacrolimus Therapeutic Levels in Renal Transplant Children. 2016 Transplant. Proc. pmid:27110018
Hashi S et al. Assessment of four methodologies (microparticle enzyme immunoassay, chemiluminescent enzyme immunoassay, affinity column-mediated immunoassay, and flow injection assay-tandem mass spectrometry) for measuring tacrolimus blood concentration in Japanese liver transplant recipients. 2014 Transplant. Proc. pmid:24767342
Uemoto S et al. Safety and efficacy of once-daily modified-release tacrolimus in liver transplant recipients: a multicenter postmarketing surveillance in Japan. 2014 Transplant. Proc. pmid:24767340
García-Bello JA et al. Effect of Immunosuppressive Therapy on Cardiovascular Risk Factor Prevalence in Kidney-Transplanted Children: Comparative Study. 2016 Transplant. Proc. pmid:27110020
Braun F et al. Primary low-dose tacrolimus immunosuppressive prophylaxis for high-risk kidney transplant recipients. 1998 Transplant. Proc. pmid:9636496
Tanabe K et al. Long-term results of living kidney transplantation under tacrolimus immunosuppression: a single-center experience. 1998 Transplant. Proc. pmid:9636497
Stratta RJ et al. Preliminary experience with FK 506 in pancreas transplant recipients. 1995 Transplant. Proc. pmid:8539823